Press Esc to close · ⌘+K to reopen
Topic
When a fusion energy company and a decarbonization SPAC find each other, the real question is not about the technology. It is about whether public markets can hold long-duration science assets.
A routine earnings disclosure from a $4.6 billion aerospace conglomerate is a reference point, not a headline, and knowing the difference is the job.
When one institution writes the whole check in a private placement, the terms inside the agreement matter more than the headline number.
Four delinquency notices in one week is not noise. It is a pattern worth understanding before your prime broker acts on it first.
A May 27 8-K from Translational Development Acquisition Corp. starts a defined sequence of events that every SPAC arbitrage desk and hard-tech capital allocator should map now.
A dual same-day 425 filing on a 100 million share all-stock deal with AZIO AI compresses the legal timeline and resets the investable entity for anyone holding EV or ESG exposure.
A Form 425 filing is not news. It is a timer. Knowing what it starts tells you more than the headline.
A SEC-registered nuclear energy company is not just a Nasdaq story. It is a new class of underlying asset for real-world asset tokenization.
A Form 425 filing confirms the autonomous freight company is entering US public markets, and the window for pre-close positioning is open right now.
A $42.78 million stock-for-stock merger filed May 27, 2026 is a small deal with large implications for how enterprise AI infrastructure gets priced and assembled.
A May 26 SEC filing confirms the deal is signed and the redemption countdown has started, and that matters more than the headline valuation.
Most amended SEC filings are routine. The skill is knowing exactly what changed and why that delta is the only thing worth your time.
When small-cap companies go silent on filings, the pattern matters more than any single name.
A small pharma company just reported its best revenue quarter on record. The signal is real, but the work is not done yet.
A distressed micro-cap shareholder vote exposes the exact governance data gap that tokenization platforms have not solved.
In clinical-stage biotech, a leadership swap is rarely just a personnel decision. The compensation terms tell you what the board believes about survival and exit.
A pre-revenue biotech with a $14.5M quarterly loss just raised capital through a private placement with three warrant series attached, and the mechanics tell a specific story about dilution, distress, and where tokenized equity is heading.
An uncharacterized share offering from a China-concentrated semiconductor equipment company is not a routine disclosure. It is a risk signal that requires exhibit-level review before any position decision.
A distressed solar company's unregistered equity sale is a live signal for clean energy collateral quality and a window into how private capital is moving through the wreckage of the 2024 bankruptcy cycle.
A quarterly loss and a major capital raise in the same week reveal how companies building critical infrastructure actually finance themselves.
A pattern of exempt offerings from one small-cap operator reveals a stress point that most tokenized RWA platforms are not built to handle.
When a public company with almost no revenue uses Bitcoin as its primary balance sheet asset and loses nine figures, the risk math for every corporate treasury evaluating BTC changes.
An amended 8-K on executive departure at a nano-cap issuer is a leading indicator of governance disruption, and possibly a capital raise.
A tender offer above $1.1 billion and a Reg FD disclosure tell you more about Kraft Heinz treasury's intentions than the headline dollar figure does.
When a public quantum computing company raises money quietly, the choice to go private is itself the data point.
When a founder leaves a distressed company, the real audience is the lenders, not the press.
Private placements are replacing registered offerings for small-cap companies, and the infrastructure to tokenize these deals already exists.
One insider sale does not make a thesis, but the structure of this transaction and the company's legal position make it worth examining carefully.
A 50.75% reduction in insider ownership at a debt-heavy company is a data point, not a story. Here is how to use it.
A hydroponic retailer reporting dollar-for-dollar losses against revenue just called itself an AI infrastructure company. Here is how to read that.
When a CEO pre-announces a share sale the same week a major shareholder amends their 13D and the company changes its name, the signal is in the combination, not the individual filing.
A pattern of insider dispositions at a scrutinized insurer is a signal for fund managers and tokenization builders alike.
When a stablecoin operator becomes a reporting issuer under the Securities Exchange Act of 1934, every counterparty in the space gets a new due diligence standard to measure against.